As the UK gets to grips with what the next phase of the coronavirus (COVID-19) pandemic may bring, our community has raised a number of concerns facing people with cystic fibrosis (CF) and their families, including returning to work and school. Keith Brownlee, Director of Policy, Programmes and Support, offers an update on some of the work the Trust has been doing to support in these areas.
With the coronavirus (COVID-19) outbreak, lockdown and shielding, this year has undoubtedly been different. However, despite these hard times, the cystic fibrosis (CF) community continues to amaze us with their positivity, perseverance and dedication to our fight for a life unlimited by cystic fibrosis. To mark the end of summer, we recap some of this year’s imaginative fundraising events and extend an enormous thank to everyone who has supported us.
Two global Phase III trials using the compound tezacaftor in combination with ivacaftor (Kalydeco) have revealed its impact for people with various combinations of the cystic fibrosis (CF) gene.
